Treatment Goals for Primary Biliary Cholangitis, an Australian Perspective

Area of Science:

• Hepatology
• Autoimmune Diseases
• Clinical Therapeutics

Background:

• Primary biliary cholangitis (PBC) is an autoimmune liver disease targeting intrahepatic bile ducts, diagnosed by elevated alkaline phosphatase (ALP) and anti-mitochondrial antibodies.
• Progression can lead to cirrhosis and liver decompensation, necessitating transplantation.
• Patients often suffer from fatigue, itch, and associated conditions like osteoporosis and Sjögren's syndrome.

Purpose of the Study:

• To discuss Primary biliary cholangitis (PBC) treatment goals within the Australian healthcare context.
• To review established risk factors for PBC progression and current therapeutic strategies.
• To emphasize the importance of monitoring and personalized second-line therapy selection.

Main Methods:

• Review of current literature and clinical guidelines for PBC management.
• Analysis of risk factors influencing PBC progression.
• Discussion of ursodeoxycholic acid (UDCA) efficacy and the role of second-line therapies.

Main Results:

• Ursodeoxycholic acid (UDCA) is the primary therapy, improving transplant-free survival, but ~40% of patients require second-line treatment.
• Risk factors for progression include male gender, young age, high ALP, anti-gp210 antibodies, and significant fibrosis.
• Second-line options include obeticholic acid (OCA) and fenofibrate, with Australian reimbursement criteria based on ALP or bilirubin levels after UDCA therapy.

Conclusions:

• Normalization of ALP is a treatment target, indicating improved outcomes.
• Proactive monitoring enables personalized selection and early initiation of effective second-line therapies.
• Optimizing PBC management in Australia involves diligent patient follow-up and tailored therapeutic approaches.